gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · WVEHealthcarePharmaceuticals

Wave Life Sciences Ltd. Ordinary Shares (WVE)

$3.62+1.12%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.62▼ 54.81% in range
Nov 4, 2025Low $3.09 · High $21.31Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Wave Life Sciences closed at $3.62 on Nov 4, up 1.12%, 83.0% below its 52-week closing high. Volume of 2.7M shares was 0.92× its 20-day average (close to normal).

Split-adjusted performance: +2.8% over one month, -50.3% over six months, -56.4% over one year.

In the quarter ended Sep 30, 2026, revenue was $13.16M, up 72.9% from a year earlier, with a net margin of -470.5%.

Short interest was 21.2M shares at the Oct 15 settlement, up 14.1% from the prior report (17.0% of float, 6.5 days to cover).

Market cap$714.0M197.2M shares
Revenue · quarter$13.2M+72.9% YoY
Diluted EPS$-0.30—
P/E · TTM—P/S 10.1×
Net margin-470.5%Gross 100.0%
Dividend yieldNone
52-week range3.09 – 21.31−83.0% from high
Volume2.7M0.92× 20-day avg
Volatility · 60d51.4%Annualised
Short % of float17.0%6.5 days to cover
Net cash$430.7MCash $430.7M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.5%1M +2.8%3M −39.9%6M −50.3%YTD −78.7%1Y −56.4%3Y −33.3%5Y −17.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum25
Revenue growth83
Net margin30
Value (low P/E)—
Size67

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short21.2M+14.1% vs prior
Days to cover6.5Settled Oct 15
% of float17.0%
Short vol. 10d42.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
WVEWave Life Sciences$3.62+1.12%−50.3%+72.9%−470.5%—$714.0M
SGMTSagimet Biosciences Inc. Series A$9.99+0.40%+19.2%———$708.4MCompare
GERNGeron$1.08+16.13%−31.6%+17.2%−29.0%—$693.9MCompare
OBXObsidian Therapeutics$10.99−16.93%————$678.9MCompare
KURAKura Oncology$7.61−22.98%−20.4%+36.5%−327.3%—$677.0MCompare
DSGNDesign Therapeutics$10.63+2.80%−26.9%———$665.2MCompare
AVBPArriVent BioPharma$13.49+3.61%−54.5%———$665.2MCompare
ZVRAZevra Therapeutics$11.17+8.87%−0.7%+44.9%48.8%8.6$663.3MCompare
COLLCollegium Pharmaceutical$23.67−0.25%−35.2%+6.3%−7.5%16.1$770.6MCompare

News about Wave Life Sciences

All news →

No recent articles focused on Wave Life Sciences. 3 articles mention it in passing.

Quick answers

What does Wave Life Sciences do?
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
What is WVE's market cap?
$713.97M, based on the Nov 4 close of $3.62.
Does Wave Life Sciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of WVE is sold short?
21.2M shares, 17.0% of float, as of Oct 15, 2026.
What sector is WVE in?
Healthcare, in the Pharmaceuticals industry.

About Wave Life Sciences

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

HQ: Cambridge, MA317 employeesListed Nov 11, 2015wavelifesciences.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology